Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation
Deborah Cook,Adam Deane,François Lauzier,Nicole Zytaruk,Gordon Guyatt,Lois Saunders,Miranda Hardie,Diane Heels-Ansdell,Waleed Alhazzani,John Marshall,John Muscedere,John Myburgh,Shane English,Yaseen M Arabi,Marlies Ostermann,Serena Knowles,Naomi Hammond,Kathleen M Byrne,Marianne Chapman,Balasubramanian Venkatesh,Paul Young,Dorrilyn Rajbhandari,Alexis Poole,Abdulrahman Al-Fares,Gilmar Reis,Daniel Johnson,Mobeen Iqbal,Richard Hall,Maureen Meade,Lori Hand,Erick Duan,France Clarke,Joanna C Dionne,Jennifer L Y Tsang,Bram Rochwerg,Timothy Karachi,Francois Lamontagne,Frédérick D'Aragon,Charles St Arnaud,Brenda Reeve,Anna Geagea,Daniel Niven,Gloria Vazquez-Grande,Ryan Zarychanski,Daniel Ovakim,Gordon Wood,Karen E A Burns,Alberto Goffi,M Elizabeth Wilcox,William Henderson,David Forrest,Rob Fowler,Neill K J Adhikari,Ian Ball,Tina Mele,Alexandra Binnie,Sebastien Trop,Sangeeta Mehta,Ingrid Morgan,Osama Loubani,Meredith Vanstone,Kirsten Fiest,Emmanuel Charbonney,Yiorgos A Cavayas,Patrick Archambault,Oleksa G Rewa,Vincent Lau,Arnold S Kristof,Kosar Khwaja,David Williamson,Salmaan Kanji,Eric Sy,Brittany Dennis,Steve Reynolds,Francois Marquis,François Lellouche,Adam Rahman,Paul Hosek,Jeffrey F Barletta,Robert Cirrone,Mark Tutschka,Feng Xie,Laurent Billot,Lehana Thabane,Simon Finfer,REVISE Investigators
DOI: https://doi.org/10.1056/NEJMoa2404245
2024-07-04
Abstract:Background: Whether proton-pump inhibitors are beneficial or harmful for stress ulcer prophylaxis in critically ill patients undergoing invasive ventilation is unclear. Methods: In this international, randomized trial, we assigned critically ill adults who were undergoing invasive ventilation to receive intravenous pantoprazole (at a dose of 40 mg daily) or matching placebo. The primary efficacy outcome was clinically important upper gastrointestinal bleeding in the intensive care unit (ICU) at 90 days, and the primary safety outcome was death from any cause at 90 days. Multiplicity-adjusted secondary outcomes included ventilator-associated pneumonia, Clostridioides difficile infection, and patient-important bleeding. Results: A total of 4821 patients underwent randomization in 68 ICUs. Clinically important upper gastrointestinal bleeding occurred in 25 of 2385 patients (1.0%) receiving pantoprazole and in 84 of 2377 patients (3.5%) receiving placebo (hazard ratio, 0.30; 95% confidence interval [CI], 0.19 to 0.47; P<0.001). At 90 days, death was reported in 696 of 2390 patients (29.1%) in the pantoprazole group and in 734 of 2379 patients (30.9%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.85 to 1.04; P = 0.25). Patient-important bleeding was reduced with pantoprazole; all other secondary outcomes were similar in the two groups. Conclusions: Among patients undergoing invasive ventilation, pantoprazole resulted in a significantly lower risk of clinically important upper gastrointestinal bleeding than placebo, with no significant effect on mortality. (Funded by the Canadian Institutes of Health Research and others; REVISE ClinicalTrials.gov number, NCT03374800.).